This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: AxoGen, Inc.
Reflects Growing Interest in AxoGen’s Peripheral Nerve Products from Orthopedic Surgeons.
Alachua, FL (PRWEB) March 18, 2013
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the commercialization of proprietary products and technologies for peripheral nerve reconstruction and regeneration, announced today that it will be highlighting its products at the American Academy of Orthopedic Surgeons (AAOS) 2013 Annual Meeting, March 19-22, 2013 at McCormick Place in Chicago. The AxoGen booth (#4750) will be featured in the First-Time Exhibitor section where attendees can view new and exciting technologies in orthopedic surgery.
Jill Schiaparelli, Senior Vice President, Business Strategy & Marketing, said, “AxoGen is excited to be presenting at the AAOS 2013 Annual Meeting for the first time. There has been increasing demand for our products by orthopedic surgeons who repair injured peripheral nerves. The AAOS 2013 meeting is the largest orthopedic meeting in the world and an excellent opportunity to highlight our nerve repair technologies with this important market segment. Our booth will feature our full suite of products: Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector.”
The AAOS has more than 36,000 members worldwide. The Annual Meeting is the largest orthopedic meeting in the world, featuring presentations of scientific papers, scientific poster and technical exhibits, instructional courses, educational symposia, and company exhibits.
About AxoGen, Inc.
AxoGen (AXGN) is a regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve reconstruction solutions including Avance® Nerve Graft, the only commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ECM coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. For more information, visit our website at http://www.axogeninc.com.
AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/3/prweb10540559.htm